

Statement of Withdrawal of the Study
Sponsor : Incyte Corporation
Study # : INCB39110-205 (EudraCT#2015-001642-28)
Product: INCB39110
Study Title : A Randomized, Double-blind Phase 2 Study of Itacitinib in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Phase: II
Study Period: NA
Centres: NA
Number of Subjects: 0
Publications: NA
Statement on withdrawal of the study: This study was prematurely ended prior to the start of enrollment by the Sponsor due to difficulty in enrollment. Globally no subjects were enrolled into the study. Therefore no results / data are available.